Pediatric Drugs

, Volume 6, Issue 2, pp 107–122


Evolving Therapies for a Disease with Many Faces
Review Article

DOI: 10.2165/00148581-200406020-00004

Cite this article as:
Goldsby, R.E. & Matthay, K.K. Pediatr-Drugs (2004) 6: 107. doi:10.2165/00148581-200406020-00004


Neuroblastoma is the most common extra-cranial solid tumor in children and has a heterogeneous clinical presentation and course. Clinical and biologic features of this disease have been used to develop risk-based therapy. Patients with low-risk disease can be treated with surgery alone. Patients with intermediate-risk features have an excellent prognosis after treatment with surgery and a relatively short course of standard dose chemotherapy. Unfortunately, most children with neuroblastoma present with advanced disease. More than 60% of patients with high-risk features will succumb to their disease despite intensive therapy including a myeloablative consolidation. Research efforts to understand the biologic basis of neuroblastoma and to identify new, more effective therapies are essential to improve the outcome for these children.

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Division of Pediatric Hematology/OncologyUniversity of California School of MedicineSan FranciscoUSA

Personalised recommendations